Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Thorax logoLink to Thorax
. 1999 May;54(5):380–383. doi: 10.1136/thx.54.5.380

Systematic review of antistaphylococcal antibiotic therapy in cystic fibrosis

K McCaffery 1, R Olver 1, M Franklin 1, S Mukhopadhyay 1
PMCID: PMC1763784  PMID: 10212099

Abstract

BACKGROUND—The respiratory tract in patients with cystic fibrosis is frequently colonised with Staphylococcus aureus. There is great diversity of clinical practice in this area of cystic fibrosis. A systematic review was conducted to study the evidence relating antistaphylococcal therapy to clinical outcome in patients with cystic fibrosis.
METHODS—A search strategy already evaluated for the study of the epidemiology of cystic fibrosis clinical trials was used. This yielded 3188 references from which 13 clinical trials of antistaphylococcal therapy were identified.
RESULTS—Substantial heterogeneity was observed between trials. In the 13 clinical trials a total of 19 antibiotics were used to assess a wide variety of outcome measures (11 clinical, six laboratory). Both intermittent and continuous treatment strategies were used. Sputum clearance of S aureus was more frequently achieved than any other beneficial outcome. A beneficial effect on pulmonary function was rarely measured or observed. Although five randomised clinical trials were identified, the extent of heterogeneity precluded the use of meta-analysis for further synthesis of information.
CONCLUSIONS—Antistaphylococcal treatment achieves sputum clearance of S aureus in patients with cystic fibrosis. Prophylactic antistaphylococcal treatment in young children with cystic fibrosis is likely to be of clinical benefit. It remains to be determined whether the use of "prophylactic" versus "intermittent" antistaphylococcal therapy in cystic fibrosis is associated with improved lung function and/or chest radiographic scores, an increase in bacterial resistance, or earlier acquisition of Pseudomonas aeruginosa. A large randomised clinical trial lasting approximately two years is urgently required to address this problem.



Full Text

The Full Text of this article is available as a PDF (94.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ballestero S., Villaverde R., Escobar H., Baquero F. Susceptibility to various antimicrobial agents of Staphylococcus aureus isolates from cystic fibrosis patients. Eur J Clin Microbiol Infect Dis. 1992 Dec;11(12):1193–1194. doi: 10.1007/BF01961145. [DOI] [PubMed] [Google Scholar]
  2. Beardsmore C. S., Thompson J. R., Williams A., McArdle E. K., Gregory G. A., Weaver L. T., Simpson H. Pulmonary function in infants with cystic fibrosis: the effect of antibiotic treatment. Arch Dis Child. 1994 Aug;71(2):133–137. doi: 10.1136/adc.71.2.133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brown J. Efficacy of antimicrobial drugs against staphylococci in cystic fibrosis. Aust Paediatr J. 1980 Sep;16(3):207–209. doi: 10.1111/j.1440-1754.1980.tb01299.x. [DOI] [PubMed] [Google Scholar]
  4. Dickersin K., Scherer R., Lefebvre C. Identifying relevant studies for systematic reviews. BMJ. 1994 Nov 12;309(6964):1286–1291. doi: 10.1136/bmj.309.6964.1286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Harrison C. J., Marks M. I., Welch D. F., Sharma B. B., Baker D., Dice J. A multicenter comparison of related pharmacologic features of cephalexin and dicloxacillin given for two months to young children with cystic fibrosis. Pediatr Pharmacol (New York) 1985;5(1):7–16. [PubMed] [Google Scholar]
  6. Jensen T., Lanng S., Faber M., Rosdahl V. T., Høiby N., Koch C. Clinical experiences with fusidic acid in cystic fibrosis patients. J Antimicrob Chemother. 1990 Feb;25 (Suppl B):45–52. doi: 10.1093/jac/25.suppl_b.45. [DOI] [PubMed] [Google Scholar]
  7. Lefebvre C. The Cochrane Collaboration: the role of the UK Cochrane Centre in identifying the evidence. Health Libr Rev. 1994 Dec;11(4):235–242. doi: 10.1046/j.1365-2532.1994.1140235.x. [DOI] [PubMed] [Google Scholar]
  8. Loening-Baucke V. A., Mischler E., Myers M. G. A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis. J Pediatr. 1979 Oct;95(4):630–637. doi: 10.1016/s0022-3476(79)80785-4. [DOI] [PubMed] [Google Scholar]
  9. Mukhopadhyay S., Singh M., Cater J. I., Ogston S., Franklin M., Olver R. E. Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. Thorax. 1996 Apr;51(4):364–368. doi: 10.1136/thx.51.4.364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ramsey B. W., Boat T. F. Outcome measures for clinical trials in cystic fibrosis. Summary of a Cystic Fibrosis Foundation consensus conference. J Pediatr. 1994 Feb;124(2):177–192. doi: 10.1016/s0022-3476(94)70301-9. [DOI] [PubMed] [Google Scholar]
  11. Shapera R. M., Warwick W. J., Matsen J. M. Clindamycin therapy of staphylococcal pulmonary infections in patients with cystic fibrosis. J Pediatr. 1981 Oct;99(4):647–650. doi: 10.1016/s0022-3476(81)80282-x. [DOI] [PubMed] [Google Scholar]
  12. Szaff M., Høiby N. Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis. Acta Paediatr Scand. 1982 Sep;71(5):821–826. doi: 10.1111/j.1651-2227.1982.tb09526.x. [DOI] [PubMed] [Google Scholar]
  13. Taylor R. F., Hodson M. E. Cystic fibrosis: antibiotic prescribing practices in the United Kingdom and Eire. Respir Med. 1993 Oct;87(7):535–539. doi: 10.1016/0954-6111(93)90010-w. [DOI] [PubMed] [Google Scholar]
  14. Weaver L. T., Green M. R., Nicholson K., Mills J., Heeley M. E., Kuzemko J. A., Austin S., Gregory G. A., Dux A. E., Davis J. A. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Arch Dis Child. 1994 Feb;70(2):84–89. doi: 10.1136/adc.70.2.84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Wright G. L., Harper J. Fusidic acid and lincomycin therapy in staphylococcal infections in cystic fibrosis. Lancet. 1970 Jan 3;1(7636):9–14. doi: 10.1016/s0140-6736(70)90523-4. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES